Philip R. Cohen, MD
Dr. Cohen is from the University of Houston Health Center, Texas; the Department of Dermatology, University of Texas MD Anderson Cancer Center, Houston; and the Department of Dermatology, University of Texas Medical School, Houston.
Dr. Cohen reports no conflicts of interest in relation to this post.
In a succinct paper, Shaw (Int J Dermatol. 2012;51:113-114) outlined not only appropriate clinic etiquette and diagnostic tips but also a humanistic approach to interacting with patients. He commented that patients are often frightened and emotionally fragile about their diagnosis; in addition, they receive a lot of information during the visit with varying needs for supplemental explanation and may not understand the dermatologic vocabulary used by physicians. He also emphasized the physician’s responsibility in helping the patient by being serious and caring. [More]
Gary Goldenberg, MD
Dr. Goldenberg is Assistant Professor, Department of Dermatology, Mount Sinai School of Medicine, New York, New York, and Medical Director of the Dermatology Faculty Practice, New York (http://www.goldenbergdermatology.com).
Dr. Goldenberg reports no conflicts of interest in relation to this post.
A review published in the Aesthetic Surgery Journal (2011;31:95-109) highlighted the use of poly-L-lactic acid (PLLA)(Sculptra Aesthetic, Valeant Aesthetics, a division of Valeant Pharmaceuticals North America) for nonsurgical rejuvenation of the aging face and restoration of facial volume. The nonsurgical, or liquid, facelift has become increasingly popular and use of PLLA is one of the cornerstones of this procedure. [More]
Anthony M. Rossi, MD
Dr. Rossi is a Fellow in Procedural Dermatology and Mohs Surgery, Memorial Sloan-Kettering and Weill Cornell/New York-Presbyterian Hospital, both in New York, New York.
Dr. Rossi reports no conflicts of interest in relation to this post.
The September 2012 issue of Dermatologic Surgery (2012;38:1497-1505) featured a randomized double-blind study to compare the safety, efficacy, and dose-response relationship of 2 doses of onabotulinumtoxinA for the treatment of hyperdynamic perioral rhytides. Sixty female participants were randomized in a 1:1 ratio to receive either 7.5 or 12.0 U of onabotulinumtoxinA at 4 perioral sites. Participants were then assessed at weeks 2, 4, 8, 12, 16, and 20. The severity of the perioral lines and participant satisfaction were assessed at all visits. [More]